Onconetix shareholders elect directors and approve reverse stock split, equity plan amendments

Onconetix, Inc.

Timothy Ramdeen and Ajit Singh were elected as Class III directors with 6,238,121 and 6,368,501 votes for, respectively.
Approved reverse stock split at ratio between 1:30 and 1:60, with 12,403,389 votes for.
Approved 2022 Equity Incentive Plan amendment increasing authorized shares by 54,850,000 (58,000,000 total), 4,956,245 votes for.
Approved issuance of up to 5,709,935 shares upon Series A conversion and 269,672,900 shares upon Series B conversion.
Ratified EisnerAmper LLP as independent auditor for FY2024 with 13,323,616 votes for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.